Adherence to Statin Treatment in Patients with Familial Hypercholesterolemia: a Dynamic Prediction Model
Familial hypercholesterolemia (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - December 23, 2022 Category: Lipidology Authors: Arjen J. Cupido, Michel H. Hof, Lotte M. de Boer, Roeland Huijgen, Erik S.G. Stroes, John J.P. Kastelein, G. Kees Hovingh, Barbara A. Hutten Tags: Original Research Source Type: research
Counseling Couples at Risk of Having a Child with Homozygous Familial Hypercholesterolemia – Clinical Experience and Recommendations
Heterozygous familial hypercholesterolemia (HeFH) is an autosomal dominant genetic disorder with a prevalence of approximately 1 in 3001, characterized by elevated low-density lipoprotein cholesterol (LDL-C) causing accelerated atherosclerosis and increased risk of premature cardiovascular disease (CVD). Early detection and initiation of lipid-lowering therapy (LLT) are crucial to negate this elevated risk.2,3 HeFH is caused by a pathogenic variant in genes encoding proteins involved in cholesterol metabolism (LDLR, APOB or PCSK9). (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - December 23, 2022 Category: Lipidology Authors: Tycho R. Tromp, M. Doortje Reijman, Albert Wiegman, G. Kees Hovingh, Joep C. Defesche, Merel C. van Maarle, Inge B. Mathijssen Tags: Brief Communication Source Type: research
Impact of telehealth on the current and future practice of lipidology: a scoping review
Clinicians have used telehealth services for decades and evidence shows that it reduces hospital readmissions, increases savings for both patients and providers, and enhances quality of patient care.1 According to the World Health Organization, telemedicine is defined as the use of information and communication technologies to improve patient outcomes by increasing access to care and medical information.2 The American Telemedicine Association considers telemedicine to be synonymous with telehealth. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - December 16, 2022 Category: Lipidology Authors: Tyler J. Schubert, Katarina Clegg, Dean Karalis, Nihar R. Desai, Joel C. Marrs, Catherine McNeal, Guy L. Mintz, Katrina M. Romagnoli, Laney K. Jones Tags: Review Article Source Type: research
Sex differences in LDL-C response to PCSK9 inhibitors: A real world experience
Low-density lipoprotein cholesterol (LDL-C) is a well-established and important cardiovascular risk factor. HMG-CoA reductase inhibitor (statin) therapy is the first line of lipid-lowering treatment for atherosclerotic cardiovascular disease (ASCVD) risk reduction.1-3 In the IMPROVE-IT trial, the addition of ezetimibe to statin therapy has also demonstrated a significant, if modest, additional clinical benefit on ASCVD risk reduction.4 However, residual CV risk remains a major concern. Indeed, according to results from the HELLAS-FH registry, LDL-C target attainment using the 2019 ESC/EAS guidelines was 2.7%. (Source: Jour...
Source: Journal of Clinical Lipidology - December 7, 2022 Category: Lipidology Authors: Martine Paquette, Simon Faubert, Nathalie Saint-Pierre, Alexis Baass, Sophie Bernard Tags: Original Research Source Type: research
Efficacy and safety of pelacarsen in lowering Lp(a) in healthy Japanese subjects
Lipoprotein(a) [Lp(a)] is a unique lipoprotein composed of apolipoprotein(a) covalently bound to apolipoprotein B-100 of an LDL-like particle.1,2 The strong and consistent genetic and epidemiological evidence of elevated Lp(a) as an independent risk factor for cardiovascular disease and aortic stenosis has generated intense interest in developing novel therapies to lower plasma levels.3 Due to the fact that Lp(a) levels are primarily determined by the synthetic rate of apolipoprotein(a) in hepatocytes, liver-targeted therapies are ideally suited to treat elevated Lp(a). (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - December 7, 2022 Category: Lipidology Authors: Ewa Karwatowska ‑Prokopczuk, Anastasia Lesogor, Jing-He Yan, Eunju Hurh, Angelika Hoenlinger, Alison Margolskee, Shuting Xia, Sotirios Tsimikas Tags: Original Research Source Type: research
Impact of the eicosapentaenoic acid to arachidonic acid ratio on plaque characteristics in statin-treated patients with coronary artery disease
A low eicosapentaenoic acid (EPA)/arachidonic acid (AA) ratio is an indicator of increased risk for cardiovascular events 1,2. Preclinical and clinical studies have demonstrated that EPA stabilizes plaques by inducing an anti-inflammatory response and reducing platelet aggregation 3,4,5. In contrast, AA facilitates plaque instability through the activation of inflammatory processes and platelet activation 6,7. Thus, having a low EPA/AA ratio may destabilize and progress the coronary plaques and cause subsequent adverse coronary event 8,9. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - December 2, 2022 Category: Lipidology Authors: Kiyoshi Asakura, Yoshiyasu Minami, Takako Nagata, Masahiro Katamine, Aritomo Katsura, Takuya Hashimoto, Daisuke Kinoshita, Junya Ako Tags: Original Research Source Type: research
Statin therapy for primary prevention in men: What is the role for coronary artery calcium?
Statin therapy is widely prescribed for patients with established ASCVD (secondary prevention). Meta-analysis of randomized clinical trials (RCTs) show conclusively that statins substantially reduce recurrent major ASCVD events (myocardial infarction and stroke)1. More problematic is use of statins for patients without ASCVD (primary prevention). RCTs clearly demonstrate that statins can lower ASCVD for primary prevention in patients at higher risk for future vascular events2-4; however, the number needed to treat (NNT) to prevent one ASCVD event is much higher for primary prevention than for secondary prevention. (Source:...
Source: Journal of Clinical Lipidology - November 23, 2022 Category: Lipidology Authors: Scott M. Grundy, Jijia Wong, Gloria L. Vega Source Type: research
Recurrence for patients with first episode of hypertriglyceridemia-induced acute pancreatitis: A prospective cohort study
Hypertriglyceridemia (HTG) is a well-established aetiology for acute pancreatitis (AP) accounting for approximately 4.7-14.3% of all cases of AP.1-3 Recurrence is of particular concern in HTG-AP, and 16-32% of patients experienced recurrent episodes in previous reports.4-6 Recurrence of HTG-AP substantially contributes to the overall disease burden by prompting repeated hospitalization, adversely impacting quality of life and increasing the risk of progression to chronic pancreatitis.7,8 (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - November 23, 2022 Category: Lipidology Authors: Ling Ding, Langyi Guan, Xueyang Li, Xin Xu, Yaoyu Zou, Cong He, Yi Hu, Jianhua Wan, Xin Huang, Yupeng Lei, Wenhua He, Liang Xia, Huifang Xiong, Lingyu Luo, Nonghua Lu, Yin Zhu Tags: Original Research Source Type: research
Management of Diabetic Dyslipidemia in Indians: Expert Consensus Statement from the Lipid Association of India
An estimated 537 million adults aged 20-79 years worldwide have diabetes mellitus, almost all type 2 diabetes.1 In India, the burden of diabetes has been increasing steadily since 1990 but the pace accelerated after the year 2000, resulting in an increase in the prevalence of diabetes from 7.1% to 8.9% between 2009 and 2019. It is estimated that the number of individuals with diabetes in India will increase from 74 million in 2021 to more than 125 million in 2045,1 primarily driven by increasing rates of elevated body mass index (BMI) and the metabolic syndrome in association with visceral adiposity. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - November 22, 2022 Category: Lipidology Authors: Raman Puri, Vimal Mehta, P. Barton Duell, SK Wangnoo, Ashu Rastogi, V Mohan, Abdul Hamid Zargar, Sanjay Kalra, Abhay Kumar Sahoo, SS Iyengar, Jamal Yusuf, Saibal Mukhopadhyay, Mani Kant Singla, Altamash Shaikh, Sunil Kohli, Sandeep Mathur, Sachin Jain, SN Tags: Original Research Source Type: research
Sex ‐related differences in premature cardiovascular disease in familial hypercholesterolemia
Familial hypercholesterolemia (FH) is an inherited condition marked by elevated blood levels of low-density lipoprotein cholesterol (LDL-C) starting in utero due most often to a monogenic mutation in the LDL-receptor. Frequency is approximately 1 in 250 in the general population and higher in several founder groups. It is well established that individuals with FH have an elevated lifetime risk of atherosclerotic cardiovascular disease (ASCVD) and are also at an increased risk of premature ASCVD (defined as (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - November 21, 2022 Category: Lipidology Authors: Anandita Agarwala, Elena Deych, Laney K. Jones, Amy C. Sturm, Karen Aspry, Zahid Ahmad, Christie M. Ballantyne, Anne C. Goldberg Tags: Original Research Source Type: research
The Independent Associations of Anti-M üllerian Hormone and Estradiol Levels over the Menopause Transition with Lipids/lipoproteins: The Study of Women's Health Across the Nation
The menopause transition (MT) is a critical stage for cardiovascular disease (CVD) risk acceleration. 1 As women traverse the MT, they experience a reduction in ovarian reserve and adverse changes in multiple CVD risk factors such as lipids and lipoproteins. Within 1 year of the final menstrual period (FMP), low density lipoprotein-cholesterol (LDL-C) and apolipoprotein B (apo B) rise sharply. 2,3 This non-linear association between lipids/lipoproteins and time relative to FMP supports a critical contribution of ovarian aging to pro-atherogenic lipid/lipoprotein changes during the MT. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - November 21, 2022 Category: Lipidology Authors: Samar R. El Khoudary, Xirun Chen, Meiyuzhen Qi, Carol A. Derby, Maria M. Brooks, Rebecca C. Thurston, Imke Janssen, Sybil Crawford, Jennifer S. Lee, Elizabeth A. Jackson, Claudia U. Chae, Daniel McConnell, Karen A. Matthews Tags: Original Research Source Type: research
Sex-Related Differences in Premature Cardiovascular Disease in Familial Hypercholesterolemia
Familial hypercholesterolemia (FH) is an inherited condition marked by elevated blood levels of low-density lipoprotein cholesterol (LDL-C) starting in utero due most often to a monogenic mutation in the LDL-receptor. Frequency is approximately 1 in 250 in the general population and higher in several founder groups. It is well established that individuals with FH have an elevated lifetime risk of atherosclerotic cardiovascular disease (ASCVD) and are also at an increased risk of premature ASCVD (defined as (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - November 21, 2022 Category: Lipidology Authors: Anandita Agarwala, Elena Deych, Laney K. Jones, Amy C. Sturm, Karen Aspry, Zahid Ahmad, Christie M. Ballantyne, Anne C. Goldberg Tags: Original Research Source Type: research
The longitudinal triglyceride phenotype in heterozygotes with LPL pathogenic variants
Hypertriglyceridemia (HTG) – i.e. elevated fasting plasma triglyceride (TG) concentration – is commonly encountered clinically.1,2 One quarter of North Americans display mild-to-moderate HTG, defined as TG levels between 2.0 to 9.9 mmol/L (175 to 875 mg/dL) while one in 400 individuals display severe HTG, defined as TG le vels> 10 mmol/L (> 875 mg/dL).2 Severe HTG in adults is associated with increased risk of acute pancreatitis and atherosclerotic cardiovascular disease (ASCVD).1 (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - November 21, 2022 Category: Lipidology Authors: Shehan D. Perera, Jian Wang, Adam D. McIntyre, Jacqueline S. Dron, Robert A. Hegele Tags: Original Research Source Type: research
Lipid profiles and hypertriglyceridemia among transgender and gender diverse adults on gender-affirming hormone therapy
Gender-affirming hormone therapy (GAHT) is common among transgender and gender-diverse adults. Transmasculine adults typically receive testosterone and transfeminine adults generally receive a combination of estrogen and an antiandrogen if they have not undergone an orchiectomy. GAHT is medically-necessary treatment taken to align physical characteristics with gender identity and to improve quality of life and psychological well-being1,2. Nonetheless, GAHT has important metabolic effects that likely alter cardiovascular risk. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - November 21, 2022 Category: Lipidology Authors: Shalem Y. Leemaqz, Mabel Kyinn, Katherine Banks, Eleanor Sarkodie, Deborah Goldstein, Michael S. Irwig Tags: Original Research Source Type: research
Genomic study of maternal lipid traits in early pregnancy concurs with four known adult lipid loci
Women's blood lipid levels undergo physiological changes during pregnancy compared to pre-pregnancy levels, and the changes are apparent in early gestational weeks1, 2. While these lipid metabolic changes during pregnancy are crucial for fetal development and maintenance of pregnancy, abnormal blood lipid levels during pregnancy are associated with increased risk for adverse pregnancy outcomes3, 4, aberrant fetal growth5-9, and later-life cardiovascular diseases for the mother10, and dyslipidemia and cardiovascular diseases in the offspring during childhood and adulthood11-13. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - November 16, 2022 Category: Lipidology Authors: Marion Ouidir, Suvo Chatterjee, Jing Wu, Fasil Tekola-Ayele Source Type: research
